| abstract |
The present invention provides a combination of plasma metabolic markers for diagnosing or monitoring colorectal cancer and application thereof, wherein the metabolic markers are selected from N-acetylphenylalanine, 1,7-dimethylxanthine, 8, 15-Dihydroxyeicosatetraenoic acid, N-acetyl-5-methoxytryptamine, 2-amino-4-hydroxypteridine, serotonin, lysophosphatidylcholine (15:0), methyl One or more combinations of maleic acid, N-methyl-alpha-aminoisobutyric acid, thymine. The 10 metabolic markers provided by the invention can accurately diagnose colorectal cancer, have high sensitivity and strong specificity, can replace the existing methods for diagnosing colorectal cancer based on blood and stool detection, reduce trauma and missed diagnosis rates, and reduce detection costs. The value of clinical use promotion. |